Dose Sparing of CpG Oligodeoxynucleotide Vaccine Adjuvants by Nanoparticle Delivery

E-ISSN： 1875-5704|1|4|405-412

ISSN： 1567-2018

Source： Current Drug Delivery, Vol.1, Iss.4, 2004-10, pp. : 405-412

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The effect of co-administration of adjuvants with a nanoparticle-based genetic vaccine delivery system on the resulting immune responses

By Cui Z. Mumper R.J.

European Journal of Pharmaceutics and Biopharmaceutics, Vol. 55, Iss. 1, 2003-01 ,pp. : 11-18

Elsevier

Access to resources Recommend Favorite

A Review of: Vaccine Adjuvants and Delivery Systems

By Middaugh Russ

Drug Development and Industrial Pharmacy, Vol. 34, Iss. 3, 2008-03 ,pp. : 347-347

Informa Healthcare

Access to resources Recommend Favorite

An Oligodeoxynucleotide with CCT Repeats Restrains CpG ODN-Induced TLR9 Trafficking

Current Pharmaceutical Biotechnology, Vol. 15, Iss. 9, 2014-09 ,pp. : 780-789

Bentham Science Publishers

Access to resources Recommend Favorite

A Review of the Role of CpG Oligodeoxynucleotides as Toll-Like Receptor 9 Agonists in Prophylactic and Therapeutic Vaccine Development in Infectious Diseases

By Gupta Kaveri

Drugs in R&D, Vol. 9, Iss. 3, 2008-01 ,pp. : 137-145

Adis International

Access to resources Recommend Favorite

Biphasic Lipid Vesicles as a Subcutaneous Delivery System for Protein Antigens and CpG Oligonucleotides

Current Drug Delivery, Vol. 3, Iss. 2, 2006-04 ,pp. : 129-135

Bentham Science Publishers

Access to resources Recommend Favorite